Form 4: C4 Therapeutics Director Boosts Stake with Stock Compensation
Insider Transaction Report
C4 Therapeutics Director Kenneth C. Anderson acquired 5,958 shares of common stock at $1.93 per share as part of his non-employee director compensation.
Summary
- Kenneth C. Anderson, a Director of C4 Therapeutics, Inc. (CCCC), acquired 5,958 shares of common stock on January 2, 2026.
- The shares were issued at a price of $1.93 per share, based on the closing market price on the transaction date.
- This acquisition was in accordance with the Issuer's Non-Employee Director Compensation Policy, where Mr. Anderson elected to receive shares instead of cash for his services.
- Following this transaction, Mr. Anderson directly beneficially owns 146,532 shares of common stock.
- Indirect beneficial ownership includes 47,316 shares held by his spouse, 61,265 shares by the Kenneth C. Anderson 2016 Grantor Retained Annuity Trust, 61,265 shares by the Cynthia E. Anderson 2016 Grantor Retained Annuity Trust, 16,939 shares by the Kenneth C. Anderson 2015 Irrevocable Trust, and 16,939 shares by the Cynthia E. Anderson 2015 Irrevocable Trust.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as a director chose to receive stock compensation, indicating confidence in the company, though it is a routine transaction and not a significant open market purchase.
Positives
- A director electing to receive common stock in lieu of cash compensation can signal confidence in the company's future prospects and align their interests with shareholders.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction filing and does not provide specific insights into broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Administrative Arrangement | A Power of Attorney was granted by Kenneth C. Anderson to several individuals (Jolie M. Siegel, Kendra Adams, Shagha T. Russell, Andrew J. Hirsch, Shoaib Ghias, and Nathan Needle) to execute and file SEC Forms (Form ID, 3, 4, 5, Schedule 13D, Schedule 13G) on his behalf, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934. | January __, 2026 (specific day not provided in exhibit) | This is a standard administrative measure to facilitate timely and accurate SEC filings for an insider, streamlining compliance processes without altering corporate governance structure or policies. |
Related Party Transactions
- The filing discloses indirect beneficial ownership of shares held by Kenneth C. Anderson's spouse and various grantor retained annuity trusts and irrevocable trusts associated with Kenneth C. Anderson and Cynthia E. Anderson.
Stakeholder Impact
- Shareholders may view the director's election to receive stock compensation as a minor positive signal of management's alignment with shareholder interests and confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/02/2026 | Date of transaction where Kenneth C. Anderson acquired common stock. |
| 01/05/2026 | Date the Form 4 was signed and filed. |
Recommendation
holdThis Form 4 details a routine compensation-related stock acquisition by a director. While the choice to receive stock over cash can be interpreted as a minor positive signal of confidence, it does not provide sufficient new information to warrant a change in investment recommendation. Investors should 'hold' and consider this as a standard insider filing.
Keywords
C4 Therapeutics, CCCC, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.